C1s2, a crucial component of the complement system, is integral to the classical pathway, orchestrating a cascade of events that contribute to innate immune responses. Predicted to enable identical protein binding activity and serine-type endopeptidase activity, C1s2 plays a pivotal role in complement activation and proteolysis. Situated in the extracellular region, this protein is active in the extracellular space, contributing to the intricate network of interactions that define the immune response. Notably, the human ortholog(s) of C1s2 are implicated in Ehlers-Danlos syndrome periodontal type 2, underscoring the significance of understanding the molecular intricacies of this complement component in health and disease.
The activation of C1s2 involves a complex interplay of molecular events that initiate and propagate the classical pathway of complement activation. Upon encountering foreign antigens, the C1 complex, comprising C1q, C1r, and C1s, binds to immunoglobulins (IgG or IgM) bound to the pathogen surface. This interaction triggers conformational changes in C1, leading to the autoactivation of C1r and subsequent activation of C1s. C1s, functioning as a serine protease, cleaves C4 and C2 to generate the C3 convertase (C4b2a), which, in turn, cleaves C3 into C3a and C3b. The generation of C3b marks the amplification loop, where further complement activation occurs, leading to opsonization, inflammation, and ultimately, pathogen clearance. C1s2's serine-type endopeptidase activity is a key contributor to the enzymatic cleavage events that propagate the complement cascade. The specific substrate recognition and cleavage by C1s2 underscore its role as a regulatory checkpoint in the immune response. The complement system, including C1s2, serves as a first-line defense against pathogens and contributes to the removal of damaged or apoptotic cells. The intricate orchestration of events involving C1s2 highlights its significance in immune surveillance and response, making it a critical target for investigation in understanding the complexities of the innate immune system.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Multikinase inhibitor that modulates the Ras/Raf/MEK/ERK pathway, indirectly influencing C1s2 activation through MAPK. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Flavonoid compound inhibiting the PI3K/Akt pathway, impacting C1s2 indirectly by downregulating Akt-mediated signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
SRC kinase inhibitor disrupting downstream signaling cascades, potentially influencing C1s2 through altered kinase activity. | ||||||
JNK Inhibitor VIII | 894804-07-0 | sc-202673 | 5 mg | $272.00 | 2 | |
Inhibitor of c-Jun N-terminal kinase (JNK), impacting the AP-1 pathway and potentially modulating C1s2 activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor disrupting the PI3K/Akt/mTOR axis, indirectly affecting C1s2 activation through suppression of mTOR. | ||||||